Clene Inc. (CLNN)
CLNN Stock Price Chart
Explore Clene Inc. interactive price chart. Choose custom timeframes to analyze CLNN price movements and trends.
CLNN Company Profile
Discover essential business fundamentals and corporate details for Clene Inc. (CLNN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Oct 2018
Employees
75.00
Website
https://clene.comCEO
Robert Etherington
Description
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
CLNN Financial Timeline
Browse a chronological timeline of Clene Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.37, while revenue estimate is $61.00k.
Earnings released on 14 May 2026
EPS came in at -$0.69 falling short of the estimated -$0.50 by -38.00%, while revenue for the quarter reached $15.00k , missing expectations by -70.44%.
Earnings released on 12 Mar 2026
EPS came in at -$0.88 falling short of the estimated -$0.74 by -18.92%, while revenue for the quarter reached $77.00k , beating expectations by +196.15%.
Earnings released on 13 Nov 2025
EPS came in at -$0.85 falling short of the estimated -$0.60 by -41.67%, while revenue for the quarter reached $15.00k , missing expectations by -76.68%.
Earnings released on 14 Aug 2025
EPS came in at -$0.78 falling short of the estimated -$0.49 by -59.18%, while revenue for the quarter reached $27.00k , missing expectations by -51.03%.
Earnings released on 7 May 2025
EPS came in at -$0.50 surpassing the estimated -$1.10 by +54.55%, while revenue for the quarter reached $81.00k , beating expectations by +26.84%.
Earnings released on 24 Mar 2025
EPS came in at -$1.67 falling short of the estimated -$1.21 by -38.02%, while revenue for the quarter reached $91.00k , missing expectations by -30.00%.
Earnings released on 13 Nov 2024
EPS came in at -$1.22 surpassing the estimated -$1.34 by +8.96%, while revenue for the quarter reached $87.00k , missing expectations by -44.23%.
Earnings released on 7 Aug 2024
EPS came in at -$1.06 surpassing the estimated -$1.60 by +33.75%, while revenue for the quarter reached $91.00k , missing expectations by -9.00%.
Stock split effective on 11 Jul 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2024
EPS came in at -$1.80 matching the estimated -$1.80, while revenue for the quarter reached $73.00k , missing expectations by -39.17%.
Earnings released on 13 Mar 2024
EPS came in at -$1.20 surpassing the estimated -$1.40 by +14.29%, while revenue for the quarter reached $170.00k , beating expectations by +21.43%.
Earnings released on 7 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$2.00 by +80.00%, while revenue for the quarter reached $108.00k , missing expectations by -10.00%.
Earnings released on 14 Aug 2023
EPS came in at -$2.40 surpassing the estimated -$2.60 by +7.69%, while revenue for the quarter reached $269.00k , beating expectations by +124.17%.
Earnings released on 12 May 2023
EPS came in at -$3.00 surpassing the estimated -$3.20 by +6.25%, while revenue for the quarter reached $107.00k , missing expectations by -17.69%.
Earnings released on 13 Mar 2023
EPS came in at -$3.20 falling short of the estimated -$3.00 by -6.67%, while revenue for the quarter reached $234.00k , beating expectations by +112.73%.
Earnings released on 7 Nov 2022
EPS came in at -$2.80 surpassing the estimated -$4.60 by +39.13%, while revenue for the quarter reached $174.00k , beating expectations by +100.77%.
Earnings released on 15 Aug 2022
EPS came in at -$4.40 falling short of the estimated -$4.20 by -4.76%, while revenue for the quarter reached $35.00k , missing expectations by -58.00%.
Earnings released on 9 May 2022
EPS came in at -$4.20 falling short of the estimated -$3.60 by -16.67%, while revenue for the quarter reached $30.00k , missing expectations by -63.86%.
Earnings released on 11 Mar 2022
EPS came in at -$3.80 falling short of the estimated -$3.60 by -5.56%, while revenue for the quarter reached $199.00k , beating expectations by +71.18%.
Earnings released on 9 Nov 2021
EPS came in at -$0.60 surpassing the estimated -$4.40 by +86.36%, while revenue for the quarter reached $110.00k , beating expectations by +83.33%.
Earnings released on 10 Aug 2021
EPS came in at -$4.20 falling short of the estimated -$2.00 by -110.00%, while revenue for the quarter reached $201.00k , beating expectations by +19.72%.
CLNN Stock Performance
Access detailed CLNN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
